Dr. Makoto Nishimura, MD

Dr. Nishimura practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Nishimura's NPI, 1083105290, was assigned on May 23, 2018. Dr. Nishimura graduated from Other in 1997. Dr. Nishimura's New York license number on file is 294075.

Dr. Nishimura's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Nishimura's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nishimura practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Nishimura's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Nishimura's licenses on file in 2 states: New York and California.

Dmand AI lists acid reflux, colonoscopy, esophagus, stomach, or upper small intestine surgery, intestinal or bowel obstruction, pancreas or bile duct endoscopy (ERCP) and upper GI endoscopy among the conditions Dr. Nishimura treats.

CMS data shows 599 Medicare services from Dr. Nishimura across 15 procedure codes in 2024, for 404 Medicare patients. Medicare paid $63,904 for them.

CMS counts 404 Medicare patients who saw Dr. Nishimura in 2024. The largest group is 65 to 74, with 183 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nishimura's median patient age at 73, with 48% women.

In 2024, Dr. Nishimura wrote 154 Medicare Part D claims for 68 patients. 99% of them were for generic drugs. CMS names the drug for 124 of them, across 2 drugs with 11 or more claims each, at $1,622 in total drug cost. In 2023, CMS named 115 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Nishimura for performance year 2024, reported as part of a group. Dr. Nishimura accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nishimura as offering telehealth. CMS counts 305 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Nishimura, more than 95% of the clinicians it reports for that procedure.

Dmand AI links 51 papers to Dr. Nishimura, published from 2010 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Endoscopic Mucosal Resection, Stomach Neoplasms and Adenocarcinoma. Dr. Nishimura has published most often in Gastrointest Endosc. Dr. Nishimura's most frequent co-authors are Mark A. Schattner, MD, Hiroyuki Aihara, MD and Jeffrey W. Milsom, MD.

Dmand AI links Dr. Nishimura to 1 clinical trial. Conditions studied include Stomach Neoplasms and Stomach Diseases.

CMS Open Payments shows 295 general payments to Dr. Nishimura from 14 drug and device companies from 2018 to 2025. Education make up the largest share, 63% of the total. Olympus Corporation of the Americas paid the most, $134,584.

Dmand AI lists 3 awards for Dr. Nishimura, most recently 2023 Clinical Excellence Award in 2023.

Dr. Nishimura graduated from Other in 1997. Dr. Nishimura is a member of ASGE, Japan gastroenterological Endoscopy Society (JGES) and Japan Gastroenteroplogical Endscopy Society.

Dr. Nishimura is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.